Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 252

1.

Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.

Sehr T, Akgün K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T.

J Mol Med (Berl). 2019 Jun 26. doi: 10.1007/s00109-019-01812-x. [Epub ahead of print]

PMID:
31243520
2.

Spectral Analysis of Heart Rate Variability: Time Window Matters.

Li K, Rüdiger H, Ziemssen T.

Front Neurol. 2019 May 29;10:545. doi: 10.3389/fneur.2019.00545. eCollection 2019.

3.

How the depth of processing modulates emotional interference - evidence from EEG and pupil diameter data.

Schreiter ML, Chmielewski WX, Mückschel M, Ziemssen T, Beste C.

Cogn Affect Behav Neurosci. 2019 Jun 12. doi: 10.3758/s13415-019-00732-0. [Epub ahead of print]

PMID:
31190135
4.

Review: Patient-reported outcomes in multiple sclerosis care.

D'Amico E, Haase R, Ziemssen T.

Mult Scler Relat Disord. 2019 Aug;33:61-66. doi: 10.1016/j.msard.2019.05.019. Epub 2019 May 27. Review.

PMID:
31154262
5.

Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".

Akgün K, Ziemssen T.

Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263. [Epub ahead of print] No abstract available.

PMID:
31144585
6.

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.

Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, Ziemssen T.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e555. doi: 10.1212/NXI.0000000000000555. eCollection 2019 May.

7.

Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019.

Akgün K, Bornhäuser M, Ziemssen T.

Mult Scler Relat Disord. 2019 Jul;32:114-115. doi: 10.1016/j.msard.2019.05.003. Epub 2019 May 13. No abstract available.

PMID:
31103833
8.

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.

Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, Kern R, Ziemssen T.

Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136. doi: 10.1177/2040622319835136. eCollection 2019.

9.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

10.

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Proschmann U, Sehr T, Akgün K, Ziemssen T.

Mult Scler. 2019 Apr 3:1352458519837702. doi: 10.1177/1352458519837702. [Epub ahead of print] No abstract available.

PMID:
30943104
11.

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.

Akgün K, Essner U, Seydel C, Ziemssen T.

J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. Review.

12.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May.

13.

On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition.

Pertermann M, Mückschel M, Adelhöfer N, Ziemssen T, Beste C.

J Neurophysiol. 2019 May 1;121(5):1633-1643. doi: 10.1152/jn.00701.2018. Epub 2019 Feb 27.

PMID:
30811254
14.

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review.

Ziemssen T, Siepmann T.

Front Neurol. 2019 Feb 12;10:53. doi: 10.3389/fneur.2019.00053. eCollection 2019. Review.

15.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]

PMID:
30785358
16.

Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition.

Adelhöfer N, Mückschel M, Teufert B, Ziemssen T, Beste C.

Brain Struct Funct. 2019 Apr;224(3):1291-1300. doi: 10.1007/s00429-019-01839-3. Epub 2019 Jan 30.

PMID:
30701308
17.

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Ziemssen T.

Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.

PMID:
30657019
18.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

19.

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K.

Front Neurol. 2018 Dec 7;9:1071. doi: 10.3389/fneur.2018.01071. eCollection 2018.

20.

Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures.

Köhler C, Wahl H, Ziemssen T, Linn J, Kitzler HH.

Neuroimage Clin. 2019;21:101623. doi: 10.1016/j.nicl.2018.101623. Epub 2018 Dec 3.

Supplemental Content

Loading ...
Support Center